ChemBridge Corporation Screening Compounds Sign up for PNAS Online eTocs
Link: Info for AuthorsLink: Editorial BoardLink: AboutLink: SubscribeLink: AdvertiseLink: ContactLink: Sitemap Link: PNAS Home
Proceedings of the National Academy of Sciences
Link: Current Issue "" Link: Archives "" Link: Online Submission ""  Link: Advanced Search



PNAS | June 6, 2000 | vol. 97 | no. 12 | 6775-6779
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (107)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jin, S.
Right arrow Articles by Scotto, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jin, S.
Right arrow Articles by Scotto, K. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg  
What's this?

 Previous Article  | Table of Contents |  Next Article 

Medical Sciences
 Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation

Shengkan Jin*, Barbara Gorfajn*, Glynn Fairclothdagger , and Kathleen W. Scotto*,Dagger

* Molecular Pharmacology and Therapeutics Program, Memorial Sloan-Kettering Cancer Center and the Weill Graduate School of Medical Sciences of Cornell University, 1275 York Avenue, New York, NY 10021; and dagger  PharmaMar USA, 320 Putnam Avenue, Cambridge, MA 02139

Edited by Samuel J. Danishefsky, Memorial Sloan-Kettering Cancer Center, New York, NY, and approved April 3, 2000 (received for review November 29, 1999)

Ecteinascidin 743 (ET-743), a highly promising marine-based antitumor agent presently in phase II clinical trials, has been shown to interfere with the binding of minor-groove-interacting transcription factors, particularly NF-Y, with their cognate promoter elements in vitro. We have shown that NF-Y is a central mediator of activation of transcription of the human P glycoprotein gene (MDR1) by a variety of inducers and that NF-Y functions by recruiting the histone acetyltransferase PCAF to the MDR1 promoter. In the present study, we tested whether ET-743 could block activation of the MDR1 promoter by agents that mediate their effect through the NF-Y/PCAF complex. We report that physiologically relevant concentrations of ET-743 abrogate transcriptional activation of both the endogenous MDR1 gene and MDR1 reporter constructs by the histone deacetylase inhibitors as well as by UV light, with minimal effect on constitutive MDR1 transcription. Notably, this inhibition does not alter the promoter-associated histone hyperacetylation induced by histone deacetylase inhibitors, suggesting an in vivo molecular target downstream of NF-Y/PCAF binding. ET-743 is therefore the prototype for a distinct class of transcription-targeted chemotherapeutic agents and may be an efficacious adjuvant to the treatment of multidrug-resistant tumors.

Dagger To whom reprint requests should be addressed. E-mail: k-scotto{at}ski.mskcc.org.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg    What's this?


This article has been cited by other articles in HighWire Press-hosted journals:


Home page
 BloodHome page
Y. Tabe, M. Konopleva, R. Contractor, M. Munsell, W. D. Schober, L. Jin, Y. Tsutsumi-Ishii, I. Nagaoka, J. Igari, and M. Andreeff
Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells
Blood, February 15, 2006; 107(4): 1546 - 1554.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Minuzzo, M. Ceribelli, M. Pitarque-Marti, S. Borrelli, E. Erba, A. diSilvio, M. D'Incalci, and R. Mantovani
Selective Effects of the Anticancer Drug Yondelis (ET-743) on Cell-Cycle Promoters
Mol. Pharmacol., November 1, 2005; 68(5): 1496 - 1503.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Fayette, I. R. Coquard, L. Alberti, D. Ranchere, H. Boyle, and J.-Y. Blay
ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas
Oncologist, November 1, 2005; 10(10): 827 - 832.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Garcia-Carbonero, J.G. Supko, R.G. Maki, J. Manola, D.P. Ryan, D. Harmon, T.A. Puchalski, G. Goss, M.V. Seiden, A. Waxman, et al.
Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study
J. Clin. Oncol., August 20, 2005; 23(24): 5484 - 5492.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Martinez, M. Sanchez-Beato, A. Carnero, V. Moneo, J. C. Tercero, I. Fernandez, M. Navarrete, J. Jimeno, and M. A. Piris
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients
Mol. Cancer Ther., May 1, 2005; 4(5): 814 - 823.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Allavena, M. Signorelli, M. Chieppa, E. Erba, G. Bianchi, F. Marchesi, C. O. Olimpio, C. Bonardi, A. Garbi, A. Lissoni, et al.
Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production
Cancer Res., April 1, 2005; 65(7): 2964 - 2971.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Sessa, F. De Braud, A. Perotti, J. Bauer, G. Curigliano, C. Noberasco, F. Zanaboni, L. Gianni, S. Marsoni, J. Jimeno, et al.
Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
J. Clin. Oncol., March 20, 2005; 23(9): 1867 - 1874.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Lau, J. G. Supko, S. Blaney, L. Hershon, N. Seibel, M. Krailo, W. Qu, D. Malkin, J. Jimeno, M. Bernstein, et al.
A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors. A Children's Oncology Group Study
Clin. Cancer Res., January 15, 2005; 11(2): 672 - 677.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
X. Zhang, W. Wharton, Z. Yuan, S.-C. Tsai, N. Olashaw, and E. Seto
Activation of the Growth-Differentiation Factor 11 Gene by the Histone Deacetylase (HDAC) Inhibitor Trichostatin A and Repression by HDAC3
Mol. Cell. Biol., June 15, 2004; 24(12): 5106 - 5118.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Garcia-Carbonero, J.G. Supko, J. Manola, M.V. Seiden, D. Harmon, D.P. Ryan, M.T. Quigley, P. Merriam, J. Canniff, G. Goss, et al.
Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy
J. Clin. Oncol., April 15, 2004; 22(8): 1480 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Tanaka, N. Ohshima, M. Ikenoya, K. Komori, F. Katoh, and H. Hidaka
HMN-176, an Active Metabolite of the Synthetic Antitumor Agent HMN-214, Restores Chemosensitivity to Multidrug-Resistant Cells by Targeting the Transcription Factor NF-Y
Cancer Res., October 15, 2003; 63(20): 6942 - 6947.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Louneva, B. Saitta, D. J. Herrick, and S. A. Jimenez
Transcriptional Inhibition of Type I Collagen Gene Expression in Scleroderma Fibroblasts by the Antineoplastic Drug Ecteinascidin 743
J. Biol. Chem., October 10, 2003; 278(41): 40400 - 40407.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Donald, R. D. Verschoyle, P. Greaves, T. W. Gant, T. Colombo, M. Zaffaroni, R. Frapolli, M. Zucchetti, M. D'Incalci, D. Meco, et al.
Complete Protection by High-Dose Dexamethasone against the Hepatotoxicity of the Novel Antitumor Drug Yondelis (ET-743) in the Rat
Cancer Res., September 15, 2003; 63(18): 5902 - 5908.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Yague, A. L. Armesilla, G. Harrison, J. Elliott, A. Sardini, C. F. Higgins, and S. Raguz
P-glycoprotein (MDR1) Expression in Leukemic Cells Is Regulated at Two Distinct Steps, mRNA Stabilization and Translational Initiation
J. Biol. Chem., March 14, 2003; 278(12): 10344 - 10352.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Biroccio, C. Gabellini, S. Amodei, B. Benassi, D. Del Bufalo, R. Elli, A. Antonelli, M. D'Incalci, and G. Zupi
Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells
Mol. Pharmacol., March 1, 2003; 63(3): 632 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Takahashi, W. Li, D. Banerjee, Y. Guan, Y. Wada-Takahashi, M. F. Brennan, T.-C. Chou, K. W. Scotto, and J. R. Bertino
Sequence-dependent Synergistic Cytotoxicity of Ecteinascidin-743 and Paclitaxel in Human Breast Cancer Cell Lines in Vitro and in Vivo
Cancer Res., December 1, 2002; 62(23): 6909 - 6915.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Scotlandi, S. Perdichizzi, M. C. Manara, M. Serra, S. Benini, V. Cerisano, R. Strammiello, M. Mercuri, G. Reverter-Branchat, G. Faircloth, et al.
Effectiveness of Ecteinascidin-743 against Drug-sensitive and -resistant Bone Tumor Cells
Clin. Cancer Res., December 1, 2002; 8(12): 3893 - 3903.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Kanzaki, Y. Takebayashi, X.-Q. Ren, H. Miyashita, S. Mori, S.-i. Akiyama, and Y. Pommier
Overcoming Multidrug Drug Resistance in P-Glycoprotein/MDR1-overexpressing Cell Lines by Ecteinascidin 743
Mol. Cancer Ther., December 1, 2002; 1(14): 1327 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. P. Ryan, T. Puchalski, J. G. Supko, D. Harmon, R. Maki, R. Garcia-Carbonero, C. Kuhlman, J. Winkelman, P. Merriam, T. Quigley, et al.
A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors
Oncologist, December 1, 2002; 7(6): 531 - 538.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Gajate, F. An, and F. Mollinedo
Differential Cytostatic and Apoptotic Effects of Ecteinascidin-743 in Cancer Cells. TRANSCRIPTION-DEPENDENT CELL CYCLE ARREST AND TRANSCRIPTION-INDEPENDENT JNK AND MITOCHONDRIAL MEDIATED APOPTOSIS
J. Biol. Chem., October 25, 2002; 277(44): 41580 - 41589.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Reid, M. J. Kuffel, S. L. Ruben, J. J. Morales, K. L. Rinehart, D. P. Squillace, and M. M. Ames
Rat and Human Liver Cytochrome P-450 Isoform Metabolism of Ecteinascidin 743 Does Not Predict Gender-dependent Toxicity in Humans
Clin. Cancer Res., September 1, 2002; 8(9): 2952 - 2962.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Donald, R. D. Verschoyle, R. Edwards, D. J. Judah, R. Davies, J. Riley, D. Dinsdale, L. L. Lazaro, A. G. Smith, T. W. Gant, et al.
Hepatobiliary Damage and Changes in Hepatic Gene Expression Caused by the Antitumor Drug Ecteinascidin-743 (ET-743) in the Female Rat
Cancer Res., August 1, 2002; 62(15): 4256 - 4262.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Friedman, Z. Hu, E. A. Kolb, B. Gorfajn, and K. W. Scotto
Ecteinascidin-743 Inhibits Activated but not Constitutive Transcription
Cancer Res., June 1, 2002; 62(12): 3377 - 3381.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. D'Incalci, E. Erba, G. Damia, E. Galliera, L. Carrassa, S. Marchini, R. Mantovani, G. Tognon, R. Fruscio, J. Jimeno, et al.
Unique Features of the Mode of Action of ET-743
Oncologist, June 1, 2002; 7(3): 210 - 216.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Villalona-Calero, S. G. Eckhardt, G. Weiss, M. Hidalgo, J. H. Beijnen, C. van Kesteren, H. Rosing, E. Campbell, M. Kraynak, L. Lopez-Lazaro, et al.
A Phase I and Pharmacokinetic Study of Ecteinascidin-743 on a Daily x 5 Schedule in Patients with Solid Malignancies
Clin. Cancer Res., January 1, 2002; 8(1): 75 - 85.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J.-M. Yang, A. D. Vassil, and W. N. Hait
Activation of Phospholipase C Induces the Expression of the Multidrug Resistance (MDR1) Gene through the Raf-MAPK Pathway
Mol. Pharmacol., October 1, 2001; 60(4): 674 - 680.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Takahashi, W. W. Li, D. Banerjee, K. W. Scotto, and J. R. Bertino
Sequence-dependent Enhancement of Cytotoxicity Produced by Ecteinascidin 743 (ET-743) with Doxorubicin or Paclitaxel in Soft Tissue Sarcoma Cells
Clin. Cancer Res., October 1, 2001; 7(10): 3251 - 3257.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. W. Li, N. Takahashi, S. Jhanwar, C. Cordon-Cardo, Y. Elisseyeff, J. Jimeno, G. Faircloth, and J. R. Bertino
Sensitivity of Soft Tissue Sarcoma Cell Lines to Chemotherapeutic Agents: Identification of Ecteinascidin-743 as a Potent Cytotoxic Agent
Clin. Cancer Res., September 1, 2001; 7(9): 2908 - 2911.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Maki
Sarcoma
Oncologist, August 1, 2001; 6(4): 333 - 337.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
K. W. Scotto and R. A. Johnson
Transcription of MDR1: A Therapeutic Target
Mol. Interv., June 1, 2001; 1(2): 117 - 125.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Delaloge, A. Yovine, A. Taamma, M. Riofrio, E. Brain, E. Raymond, P. Cottu, F. Goldwasser, J. Jimeno, J. L. Misset, et al.
Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients--Preliminary Evidence of Activity
J. Clin. Oncol., March 1, 2001; 19(5): 1248 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Taamma, J. L. Misset, M. Riofrio, C. Guzman, E. Brain, L. Lopez Lazaro, H. Rosing, J. M. Jimeno, and E. Cvitkovic
Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors
J. Clin. Oncol., March 1, 2001; 19(5): 1256 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Takebayashi, F. Goldwasser, Y. Urasaki, G. Kohlhagen, and Y. Pommier
Ecteinascidin 743 Induces Protein-linked DNA Breaks in Human Colon Carcinoma HCT116 Cells and Is Cytotoxic Independently of Topoisomerase I Expression
Clin. Cancer Res., January 1, 2001; 7(1): 185 - 191.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Minuzzo, S. Marchini, M. Broggini, G. Faircloth, M. D'Incalci, and R. Mantovani
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
PNAS, June 6, 2000; 97(12): 6780 - 6784.
[Abstract] [Full Text] [PDF]